When it comes to maintaining body composition, preventing muscle loss on semaglutide is highly important
Discussion In this database study, treatment with semaglutide (against sitagliptin, a placebo proxy) led to a reduced risk of MACE, and tirzepatide (against dulaglutide) demonstrated a similar risk reduction in patients at elevated cardiovascular risk with obesity and type 2 diabetes
Both medications lead to muscle loss as part of the overall weight loss process
We believe that clinical weight loss support should be simple, safe, and affordable, without requiring patients to solve complex mathematical equations to determine what they will pay each month
The missing piece might be vitamin b12
To be eligible for the BELIEVE study, participants must have a body mass index (BMI) greater than or equal to 30, or greater than or equal to 27 with one or more obesity-related comorbidities